DYN Dyne Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DYN
Price (delayed)
$11.16
Market cap
$1.59B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.86
Enterprise value
$1.22B
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in
Highlights
DYN's net income has shrunk by 60% YoY and by 12% QoQ
Dyne Therapeutics's quick ratio has decreased by 37% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of DYN
Market
Valuations
Earnings
Shares outstanding
142.26M
Market cap
$1.59B
Enterprise value
$1.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$440.93M
Net income
-$412.89M
EBIT
-$412.79M
EBITDA
-$410.59M
Free cash flow
-$361.93M
Per share
Balance sheet
Liquidity
EPS
-$3.86
EPS diluted
-$3.86
Free cash flow per share
-$3.18
Book value per share
$5.03
Revenue per share
$0
TBVPS
$6.4
Total assets
$728.99M
Total liabilities
$157.55M
Debt
$121.08M
Equity
$571.45M
Working capital
$656.48M
Debt to equity
0.21
Current ratio
16.83
Quick ratio
16.49
Net debt/EBITDA
0.89
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.8%
Return on equity
-64.1%
Return on invested capital
-162.9%
Return on capital employed
-60%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DYN stock price
How has the Dyne Therapeutics stock price performed over time
Intraday
-0.27%
1 week
11.04%
1 month
33.02%
1 year
-74.09%
YTD
-52.63%
QTD
17.23%
Financial performance
How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$440.93M
Net income
-$412.89M
Gross margin
N/A
Net margin
N/A
DYN's operating income has shrunk by 63% YoY and by 11% QoQ
DYN's net income has shrunk by 60% YoY and by 12% QoQ
Price vs fundamentals
How does DYN's price correlate with its fundamentals
Growth
What is Dyne Therapeutics's growth rate over time
Valuation
What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is down by 8% since the previous quarter and by 8% year-on-year
The price to book (P/B) is 28% lower than the last 4 quarters average of 3.1 and 26% lower than the 5-year quarterly average of 3.0
The equity has contracted by 26% YoY and by 15% from the previous quarter
Efficiency
How efficient is Dyne Therapeutics business performance
The return on equity has declined by 21% since the previous quarter but it is up by 7% year-on-year
The company's return on assets fell by 16% QoQ but it rose by 5% YoY
DYN's return on invested capital is up by 13% year-on-year
Dividends
What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DYN.
Financial health
How did Dyne Therapeutics financials performed over time
Dyne Therapeutics's current ratio has decreased by 37% YoY and by 17% from the previous quarter
Dyne Therapeutics's quick ratio has decreased by 37% YoY and by 18% from the previous quarter
The debt is 79% smaller than the equity
The equity has contracted by 26% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.